Heron Therapeutics (HRTX) Gross Margin (2017 - 2026)

Heron Therapeutics (HRTX) has reported Gross Margin for 10 consecutive years, with 69.28% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin fell 423.0% year-over-year to 69.28%; the trailing twelve-month figure through Jun 2026 stood at 70.07% (down 454.0% YoY), and the FY2025 full-year result was 73.31%, up 9.0% from the prior year.
• Gross Margin steadied at 69.28% in Q2 2026 per HRTX's latest filing, from 69.35% in the prior quarter.
• Across five years, Gross Margin topped out at 78.26% in Q1 2025 and bottomed at 36.53% in Q2 2023.
• Historically, Gross Margin has averaged 61.82% across 5 years, with a median of 69.31% in 2026.
• The sharpest annual moves came in 2024 and 2026: Gross Margin soared 3427 bps in 2024, then tumbled 891 bps in 2026.
• Over 5 years, Gross Margin stood at 57.95% in 2022, then advanced by 23 bps to 71.12% in 2023, then climbed by 5 bps to 74.92% in 2024, then fell by 3 bps to 72.61% in 2025, then dropped by 5 bps to 69.28% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 69.28%, 69.35%, and 72.61% for Q2 2026, Q1 2026, and Q4 2025 respectively.